ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1 (open-label), multi-center study arm will investigate evorpacept, a CD47 blocker, in combination with ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody-drug conjugate, to determine the safety, tolerability and efficacy of this drug combination.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 USD | -10.50% |
|
-15.15% | -60.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.51% | 306M | |
+16.49% | 122B | |
+21.73% | 115B | |
+20.84% | 26.64B | |
-21.81% | 19.91B | |
-16.84% | 16.32B | |
-44.74% | 15.52B | |
-18.81% | 15.49B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer